Compare EQ & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQ | FSP |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 72.4M |
| IPO Year | 2018 | 2001 |
| Metric | EQ | FSP |
|---|---|---|
| Price | $2.26 | $0.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 384.6K | 354.2K |
| Earning Date | 05-25-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | N/A | ★ 15.69 |
| EPS | ★ N/A | N/A |
| Revenue | $41,095,000.00 | ★ $107,162,000.00 |
| Revenue This Year | N/A | $17.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $0.56 |
| 52 Week High | $2.70 | $1.88 |
| Indicator | EQ | FSP |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 41.92 |
| Support Level | $1.60 | $0.56 |
| Resistance Level | $2.35 | $0.71 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 71.07 | 20.91 |
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.